Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 8/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 3/20 | 0.40 |
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
| ▸ | PLG | P00747 | 1/20 | 0.40 |
| ▸ | F11 | P03951 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.38 |
| ▸ | TACR2 | P21452 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4650317 | 0.93 | KMT2A (0.41) | KMT2ASRCGRIA1CTSLL3MBTL1 | |
| SCHEMBL7049668 | 0.87 | SRC (0.45) | KMT2ASRCGRIA1CTSLL3MBTL1 | |
| SCHEMBL7049667 | 0.84 | SRC (0.42) | KMT2ASRCGRIA1CTSLL3MBTL1 | |
| SCHEMBL7049670 | 0.83 | SRC (0.42) | KMT2ASRCGRIA1CTSLL3MBTL1 | |
| SCHEMBL7052132 | 0.81 | L3MBTL1 (0.42) | KMT2ASRCGRIA1CTSLL3MBTL1 | |
| SCHEMBL4650855 | 0.80 | KMT2A (0.47) | KMT2ASRCGRIA1CTSLL3MBTL1 | |
| SCHEMBL14066218 | 0.78 | SRC (0.48) | KMT2ASRCGRIA1CTSLL3MBTL1 | |
| SCHEMBL4650362 | 0.77 | GRIA1 (0.55) | KMT2ASRCGRIA1CTSLL3MBTL1 | |
| SCHEMBL7052133 | 0.77 | L3MBTL1 (0.41) | KMT2ASRCGRIA1CTSLL3MBTL1 | |
| SCHEMBL4651392 | 0.72 | GRIA1 (0.73) | KMT2AGRIA1CTSLL3MBTL1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1301474-B1 | TYROSINE DERIVATIVES AS PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2008-09-10 | — | — | EP | disclosed |
| US-6586467-B2 | Tyrosine phosphatase inhibitors useful in the treatment or prevention of Type II Diabetes Mellitus | ARRAY BIOPHARMA INC. | 2003-07-01 | — | — | US | disclosed |
| US-20020040003-A1 | Preparation of phosphatase inhibitors | ARRAY BIOPHARMA INC. | 2002-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040003-A1 | Preparation of phosphatase inhibitors | PTPRS, PTPRO, PTPRR | KMT2A 3124/4885SRC 176/4885GRIA1 2535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.